Vimarsana
Biggest News Aggregation in the World

Christopher Powala News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Christopher Powala. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Christopher Powala Today - Breaking & Trending Today

NFlection Therapeutics Announces Orphan Drug Designation of NFX-179 for the Treatment of Cutaneous Neurofibromatosis Type 1 - Vimarsana News

NFlection Therapeutics Announces Orphan Drug Designation of NFX-179 for the Treatment of Cutaneous Neurofibromatosis Type 1

Published: August 18, 2021

NFlection Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for rare RASopathies, today announced that the Food and Drug Administration has...

Source: marketscreener.com
Related Topics:
United StatesChristopher PowalaOffice Of Orphan Drug ProductsDrug AdministrationNflection Therapeutics IncOrphan Drug ProductsChief Executive Officerஒன்றுபட்டது மாநிலங்களில்அலுவலகம் ஆஃப் ஆர்ஃபந் மருந்து ப்ராடக்ட்ஸ்ஆர்ஃபந் மருந்து ப்ராடக்ட்ஸ்தலைமை நிர்வாகி அதிகாரி
Topical MEK Inhibitor, NFX-179, Prevents Cutaneous Squamous Cell Carcinoma in Pre-Clinical Model - Vimarsana News

Topical MEK Inhibitor, NFX-179, Prevents Cutaneous Squamous Cell Carcinoma in Pre-Clinical Model

Published: May 4, 2021

/PRNewswire/ -- In research to be shared during a plenary talk at the Society for Investigative Dermatology's 2021 Virtual Meeting, data from investigators at...

Source: prnewswire.com
Related Topics:
United StatesKenneth TsaiGuy WebsterChristopher PowalaTsai LabNflection Therapeutics IncStanford University School Of MedicineTsai Lab At Moffitt Cancer CenterSociety For Investigative DermatologySarin LabTumor Biology At Moffitt Cancer CenterInvestigative DermatologyMoffitt Cancer CenterStanford University SchoolSenior MemberAnatomic PathologyTumor BiologyMoffitt CancerSolid Organ TransplantChief Medical OfficerPrecision TargetedPlenary SessionChemopreventative TargetSquamous CellNflection Therapeutics